AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11806988 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day prednisone (PDN) pretreatment
Number of subjects: 778
Study 11806988 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional 4-drug induction with cyclophosphamide
Number of subjects: 778
Study 11806988 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction intensification (8-drug consolidation)
Number of subjects: 778
Study 11806988 — intervention group
Group type: COMPARATOR
Intervention: Maintenance alone
Number of subjects: 778
Study 11806988 — intervention group
Group type: COMPARATOR
Intervention: Consolidation followed by maintenance
Number of subjects: 778
Study 11806988 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 778
Study 11806988 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous complete remission (CCR)
Number of subjects: 778
Study 11806988 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival (DFS)
Number of subjects: 778
Study 9453332 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg daily)
Number of subjects: 9
Study 9453332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7993860 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 1548
Study 7993860 — intervention group
Group type: COMPARATOR
Intervention: Conventional cholecystectomy (CC)
Number of subjects: 1548
Study 3224162 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral propranolol every 6 hours (test dosage form)
Number of subjects: 28
Study 30124439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 78
Study 30124439 — intervention group
Group type: COMPARATOR
Intervention: Thermography
Number of subjects: 78
Study 26754586 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg pitavastatin daily + intensive lifestyle modification (LSM)
Number of subjects: 75
Study 26754586 — intervention group
Group type: COMPARATOR
Intervention: intensive lifestyle modification (LSM) only
Number of subjects: 75
Study 25762232 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 10 mg/kg/24 h intravenous plus fosfomycin 2 gr/6 g intravenous
Number of subjects: 103
Study 25762232 — intervention group
Group type: COMPARATOR
Intervention: Daptomycin 10 mg/kg/24 h intravenous
Number of subjects: 103
Study 22951572 — intervention group
Group type: EXPERIMENTAL
Intervention: RTW-E (exposure-based return-to-work intervention)
Number of subjects: 160
Study 22951572 — intervention group
Group type: COMPARATOR
Intervention: CAU (care-as-usual)
Number of subjects: 160
Study 19926385 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation
Number of subjects: 117
Study 19926385 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia
Number of subjects: 117
Study 19926385 — intervention group
Group type: COMPARATOR
Intervention: Reading
Number of subjects: 117
Study 18806109 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/d) for 6 months
Number of subjects: 2451
Study 18806109 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (10 mg/d) for 6 months
Number of subjects: 2451
Study 18806109 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2451
Study 16463145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopic management using holmium laser fragmentation with a 200 microm holmium laser fiber via a 7.5 F flexible ureteroscope.
Number of subjects: 0
Study 16463145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitinol basket or grasper retrieval for stone displacement.
Number of subjects: 0
Study 16463145 — intervention group
Group type: COMPARATOR
Intervention: Shockwave lithotripsy (SWL)
Number of subjects: 0
Study 16463145 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy (PNL)
Number of subjects: 0
Study 12542723 — intervention group
Group type: EXPERIMENTAL
Intervention: acarbose 100 mg t.i.d.
Number of subjects: 77
Study 12542723 — intervention group
Group type: EXPERIMENTAL
Intervention: glibenclamide 1 mg t.i.d.
Number of subjects: 77
Study 12542723 — intervention group
Group type: COMPARATOR
Intervention: placebo t.i.d.
Number of subjects: 77
Study 11099583 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby CareLink telemedicine application
Number of subjects: 56
Study 11099583 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 56
Study 9014669 — intervention group
Group type: EXPERIMENTAL
Intervention: General prophylaxis with unfractionated heparin
Number of subjects: 0
Study 9014669 — intervention group
Group type: EXPERIMENTAL
Intervention: General prophylaxis with low molecular weight heparin (LMWH)
Number of subjects: 0
Study 9014669 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis against DVT
Number of subjects: 0
Study 9014669 — intervention group
Group type: COMPARATOR
Intervention: Selective treatment of DVT after confirmation of diagnosis
Number of subjects: 0
Study 1642678 — intervention group
Group type: EXPERIMENTAL
Intervention: Single administration of clentiazem (30 mg)
Number of subjects: 27
Study 1642678 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated administration of clentiazem (30 mg daily for 2 weeks)
Number of subjects: 27
Study 6650976 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (pH 5.5) at room temperature (25 degrees C)
Number of subjects: 0
Study 6650976 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline at 37 degrees C in RML, normal saline buffered to pH 7.0 at 37 degrees C in RLL, normal saline at 25 degrees C in left lingula, normal saline buffered to pH 7.0 at 25 degrees C in LLL
Number of subjects: 0
Study 29609594 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Number of subjects: 307
Study 29609594 — intervention group
Group type: COMPARATOR
Intervention: Healthy Aging Attention Control
Number of subjects: 307
Study 26976553 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin restorations
Number of subjects: 47
Study 26976553 — intervention group
Group type: COMPARATOR
Intervention: Metal-ceramic crowns
Number of subjects: 47
Study 26976553 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 47
Study 26976553 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of restoration types
Number of subjects: 47
Study 24908970 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tamoxifen therapy in combination with chemotherapy
Number of subjects: 0
Study 24908970 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 0
Study 23770971 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104 (2.0 g/day)
Number of subjects: 24
Study 23770971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20837462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 plus carboplatin AUC 6 for 4 cycles followed by maintenance pemetrexed
Number of subjects: 360
Study 20837462 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 200 mg/m2 plus carboplatin AUC 6 plus bevacizumab 15 mg/kg for 4 cycles followed by maintenance bevacizumab
Number of subjects: 360
Study 18346712 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure writing
Number of subjects: 198
Study 18346712 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefit-finding writing
Number of subjects: 198
Study 18346712 — intervention group
Group type: COMPARATOR
Intervention: Unstructured emotion writing
Number of subjects: 198
Study 16883902 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiepi Fengdou Granule (TFG)
Number of subjects: 80
Study 16883902 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiepi Fengdou Capsule (TFC)
Number of subjects: 80
Study 16883902 — intervention group
Group type: COMPARATOR
Intervention: Shengmai Capsule (Control)
Number of subjects: 80
Study 15379415 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined, structured multidisciplinary weight management program (dietary-behavioral-exercise intervention) for 12 months
Number of subjects: 77
Study 15379415 — intervention group
Group type: COMPARATOR
Intervention: Control group (obese children who did not participate in the structured program)
Number of subjects: 77
Study 11762816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate 90 mg monthly
Number of subjects: 51
Study 11762816 — intervention group
Group type: COMPARATOR
Intervention: Oral clodronate 1,600 mg daily
Number of subjects: 51
Study 11762816 — intervention group
Group type: COMPARATOR
Intervention: Intravenous clodronate followed by oral clodronate
Number of subjects: 51
Study 9260018 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (Group R)
Number of subjects: 20
Study 9260018 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (Group P)
Number of subjects: 20
Study 8315645 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress cues
Number of subjects: 83
Study 8315645 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress cues with heart attack symptoms
Number of subjects: 83
Study 8315645 — intervention group
Group type: COMPARATOR
Intervention: Age manipulation
Number of subjects: 83
Study 3565931 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced asthma (EIA)
Number of subjects: 10
Study 3565931 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic 3.6% saline challenge
Number of subjects: 10
Study 3565931 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic challenge
Number of subjects: 10
Study 3565931 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 10
Study 3565931 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine-induced bronchoconstriction
Number of subjects: 10
Study 3565931 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of isotonic saline
Number of subjects: 10
Study 3565931 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and aerosolized hypertonic saline
Number of subjects: 10
Study 31567160 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate switch to TDF/FTC/rilpivirine (RPV)
Number of subjects: 74
Study 31567160 — intervention group
Group type: COMPARATOR
Intervention: Delayed switch to TDF/FTC/rilpivirine (RPV)
Number of subjects: 74
Study 29397258 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl (PF)
Number of subjects: 136
Study 29397258 — intervention group
Group type: COMPARATOR
Intervention: Propofol-ketamine (PK)
Number of subjects: 136
Study 27908846 — intervention group
Group type: EXPERIMENTAL
Intervention: My Asthma Portal (MAP)
Number of subjects: 100
Study 27908846 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 24259556 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc citrate (10 mg)
Number of subjects: 15
Study 24259556 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate (10 mg)
Number of subjects: 15
Study 24259556 — intervention group
Group type: COMPARATOR
Intervention: Zinc oxide (10 mg)
Number of subjects: 15
Study 23202814 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods video (focused on intrauterine device and contraceptive implant)
Number of subjects: 1060
Study 23202814 — intervention group
Group type: COMPARATOR
Intervention: Motivational videos
Number of subjects: 1060
Study 23202814 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods video (in concordant positive couples)
Number of subjects: 1060
Study 23202814 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods video (in couples with HIV-positive women)
Number of subjects: 1060
Study 20861399 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 242
Study 20861399 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET)
Number of subjects: 242
Study 20861399 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 242
Study 17664051 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 150 mg/day for 12 weeks
Number of subjects: 164
Study 17664051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 16636114 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO treatment
Number of subjects: 100
Study 16636114 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 100
Study 16636114 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 12796578 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mm prosthetic H-graft portacaval shunt (HGPCS)
Number of subjects: 62
Study 12796578 — intervention group
Group type: COMPARATOR
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 62
Study 10029562 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (1.0 ng x min‐1 x kg‐1 and 3.0 ng x min‐1 x kg‐1 for 30 min)
Number of subjects: 31
Study 10029562 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (1.0 ng x min‐1 x kg‐1 and 3.0 ng x min‐1 x kg‐1 for 120 min)
Number of subjects: 31
Study 10029562 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (3.0 ng x min‐1 x kg‐1 for 30 min followed by dose increment every 30 min until mean blood pressure increased by 25 mmHg)
Number of subjects: 31
Study 10029562 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (1.0 ng x min‐1 x kg‐1 followed by 3.0 ng x min‐1 x kg‐1 for 60 min on two different NaCl diets)
Number of subjects: 31
Study 10029562 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (10(‐9), 10(‐8), 10(‐7) mol/l) in cultured human vascular endothelial cells
Number of subjects: 31
Study 10029562 — intervention group
Group type: COMPARATOR
Intervention: Candesartan cilexetil (AT1 receptor inhibitor)
Number of subjects: 31
Study 10029562 — intervention group
Group type: COMPARATOR
Intervention: Actinomycin D (RNA synthesis inhibitor)
Number of subjects: 31
Study 10029562 — intervention group
Group type: COMPARATOR
Intervention: Cycloheximide (protein synthesis inhibitor)
Number of subjects: 31
Study 7477812 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drink
Number of subjects: 0
Study 7477812 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline blood glucose levels
Number of subjects: 0
Study 7477812 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline blood glucose levels
Number of subjects: 0
Study 7477812 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drink with fail in blood glucose
Number of subjects: 0
Study 2180889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and benzylpenicillin
Number of subjects: 97
Study 2180889 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin and piperacillin
Number of subjects: 97
Study 453298 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (550 mg initially, followed by 275 mg every 6 hours as needed)
Number of subjects: 33
Study 31307843 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA supplementation (15 g daily)
Number of subjects: 42
Study 31307843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (supervised progressive vigorous treadmill walking 3 times weekly)
Number of subjects: 42
Study 31307843 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 42
Study 31307843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex with EAA supplementation (Ex + EAA)
Number of subjects: 42
Study 31307843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex with placebo (Ex + PLA)
Number of subjects: 42
Study 29538089 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Responders (TRs)
Number of subjects: 0
Study 29538089 — intervention group
Group type: COMPARATOR
Intervention: Treatment Nonresponders (TNRs)
Number of subjects: 0
Study 29538089 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-assisted treatment
Number of subjects: 0
Study 29538089 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment response
Number of subjects: 0
Study 29538089 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal estimated gestational age (EGA)
Number of subjects: 0
Study 29538089 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cocaine use
Number of subjects: 0
Study 29538089 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal education
Number of subjects: 0
Study 29538089 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment nonresponse
Number of subjects: 0
Study 29538089 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SUD treatment
Number of subjects: 0
Study 29538089 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline marijuana use
Number of subjects: 0
Study 27634054 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy monitoring
Number of subjects: 144
Study 27634054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography monitoring
Number of subjects: 144
Study 27634054 — intervention group
Group type: COMPARATOR
Intervention: No monitoring
Number of subjects: 144
Study 24614377 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose (400/100 mg BID)
Number of subjects: 60
Study 24614377 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose (600/150 mg BID)
Number of subjects: 60
Study 24614377 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose (400/100 mg BID) after childbirth
Number of subjects: 60
Study 24614377 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose (600/150 mg BID) after childbirth
Number of subjects: 60
Study 22821790 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based pharmacist intervention (patient education, home blood pressure monitoring, referral to physician)
Number of subjects: 176
Study 22821790 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based pharmacist intervention
Number of subjects: 176
Study 22821790 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 176
Study 20087081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg daily)
Number of subjects: 131
Study 20087081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 18077778 — intervention group
Group type: EXPERIMENTAL
Intervention: Elk velvet antler
Number of subjects: 168
Study 18077778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 15895892 — intervention group
Group type: EXPERIMENTAL
Intervention: High molecular weight HA (Hylan G‐F 20) injections
Number of subjects: 92
Study 15895892 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight HA (Orthovisc) injections
Number of subjects: 92
Study 15895892 — intervention group
Group type: COMPARATOR
Intervention: Both HA preparations (High molecular weight and Low molecular weight)
Number of subjects: 92
Study 14511969 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational counselling
Number of subjects: 0
Study 14511969 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care
Number of subjects: 0
Study 10502228 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected TIMI frame count (cTFC)
Number of subjects: 390
Study 10502228 — intervention group
Group type: EXPERIMENTAL
Intervention: Final TIMI flow
Number of subjects: 390
Study 10502228 — intervention group
Group type: EXPERIMENTAL
Intervention: Final TIMI flow (in patients with analyzable cTFC)
Number of subjects: 390
Study 10502228 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 390
Study 10502228 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 390
Study 10502228 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI flow grade
Number of subjects: 390
Study 10502228 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct location
Number of subjects: 390
Study 8983276 — intervention group
Group type: EXPERIMENTAL
Intervention: Large core biopsy
Number of subjects: 41
Study 1669388 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser
Number of subjects: 300
Study 1669388 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgery
Number of subjects: 300
Study 1669388 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study 7340376 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 50 μg.kg‐1
Number of subjects: 25
Study 7340376 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 10 μg.kg‐1
Number of subjects: 25
Study 7340376 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 30 μg.kg‐1
Number of subjects: 25
Study 6429481 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 17 beta-oestradiol 2 mg plus oestriol 1 mg for 12 days, followed by 17 beta-oestradiol 2 mg plus norethisterone acetate 1 mg for 10 days, and then 17 beta-oestradiol 1 mg plus oestriol 0.5 mg for 6 days
Number of subjects: 43
Study 6429481 — intervention group
Group type: COMPARATOR
Intervention: Combination of 17 beta-oestradiol 2 mg plus norethisterone acetate 1 mg for 12 days, followed by 17 beta-oestradiol 2 mg plus norethisterone acetate 1 mg for 10 days, and then 17 beta-oestradiol 1 mg for 6 days (without oestriol)
Number of subjects: 43
Study 30621368 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical manipulation
Number of subjects: 83
Study 30621368 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical mobilization
Number of subjects: 83
Study 30621368 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 83
Study 29284788 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose 1 Curry
Number of subjects: 20
Study 29284788 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose 2 Curry
Number of subjects: 20
Study 29284788 — intervention group
Group type: COMPARATOR
Intervention: Dose 0 Control
Number of subjects: 20
Study 26517858 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (titrated up to 120 mg/day)
Number of subjects: 41
Study 26517858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 26517858 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 41
Study 24255991 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing in geothermal seawater combined with NB‐UVB therapy three times a week
Number of subjects: 68
Study 24255991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive daily treatment involving bathing in geothermal seawater combined with NB‐UVB therapy
Number of subjects: 68
Study 24255991 — intervention group
Group type: COMPARATOR
Intervention: NB‐UVB therapy alone three times a week
Number of subjects: 68
Study 22153280 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal analgesia
Number of subjects: 97